Pemphigus vulgaris (PV), an acquired autoimmune bullous disease, is caused by autoantibodies targeting desmosomal proteins in the skin and mucous membranes. Recent data from the adult PV population supports the use of rituximab, a chimeric anti-CD20 IgG1 antibody, as a primary treatment strategy, but limited data exist regarding treatment in the pediatric population. We report the case of a 13-year-old male with PV treated successfully with systemic corticosteroids and rituximab, and review the literature supporting the treatment of pediatric PV with rituximab.

中文翻译：

---

用利妥昔单抗治疗小儿寻常型天疱疮：病例报告和文献复习

寻常型天疱疮 (PV) 是一种获得性自身免疫性大疱性疾病，由靶向皮肤和粘膜桥粒蛋白的自身抗体引起。来自成人 PV 人群的最新数据支持使用利妥昔单抗（一种嵌合抗 CD20 IgG1 抗体）作为主要治疗策略，但关于儿童人群治疗的数据有限。我们报告了一名患有 PV 的 13 岁男性使用全身性皮质类固醇和利妥昔单抗成功治疗的病例，并回顾了支持使用利妥昔单抗治疗小儿 PV 的文献。